Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
via Wikipedia infobox
Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
The most common side effects include upper respiratory infections (nose and throat infection)..
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).